In many countries, doctors are giving COVID-19 patients medicines that have not been approved for this disease. The use of licensed medicines for indications that have not been approved by a national medicines regulatory authority is considered “off-label” use. The prescription of medicines for off-label use by doctors may be subject to national laws and regulations. All health care workers should be aware of and comply with the laws and regulations governing their practice. Further, such prescribing should be done on a case-by-case basis. Unnecessary stockpiling and the creation of shortages of approved medicines that are required to treat other diseases should be avoided. It can be ethically appropriate to offer individual patients experimental interventions on an emergency basis outside clinical trials, provided that no proven effective treatment exists; it is not possible to initiate clinical studies immediately; the patient or his or her legal representative has given informed consent; and the emergency use of the intervention is monitored, and the results are documented and shared in a timely manner with the wider medical and scientific community.
Abstract: Clinical and Experimental Psychology
Research Article: Clinical and Experimental Psychology
Research Article: Clinical and Experimental Psychology
Research Article: Clinical and Experimental Psychology
Research Article: Clinical and Experimental Psychology
Research Article: Clinical and Experimental Psychology
Scientific Tracks Abstracts: Clinical and Experimental Psychology
Posters & Accepted Abstracts: Journal of Neurology & Neurophysiology
Scientific Tracks Abstracts: Journal of Neurology & Neurophysiology
Posters & Accepted Abstracts: Journal of Neurology & Neurophysiology
AcceptedAbstracts: Journal of Neurology & Neurophysiology
